<p>PureTech Health plc (LON:PRTC - 获取免费报告) 的股价在周二下跌了 9.2%。该公司的股价最低曾达到 126 便士，最后交易价为 126 便士。在午盘交易中，共成交了 1,066,844 股，较平均交易量 1,249,921 股下降了 15%。该股票此前收盘价为 138.80 便士。</p>
<p>获取 <strong>PureTech Health</strong> 的提醒：</p>
<h2>PureTech Health 股票表现</h2>
<p>该公司的债务与股本比率为 6.33，流动比率为 6.59，速动比率为 2.51。该股票的市值为 3.0671 亿英镑，市盈率为-2.74，贝塔值为 1.35。该股票的 50 日移动平均线为 121.85 便士，200 日移动平均线为 125.88 便士。</p>
<h2>PureTech Health 公司简介</h2>
<p>(获取免费报告)</p>
<p>PureTech Health plc 是一家临床阶段的生物制药公司，专注于开发针对神经、胃肠和免疫系统功能障碍引起的疾病的药物。该公司正在开发微生物组免疫系统药物发现平台和针对免疫介导疾病的药物候选者；以及通过口服胶囊诱导减肥和增强血糖控制的产品。它还在开发用于筛查、诊断和治疗神经系统疾病（如注意力缺陷多动障碍、自闭症和抑郁症）的技术和产品；用于精神疾病的非侵入性神经刺激治疗；以及用于精神分裂症的联合治疗。</p>
<h2>特色故事</h2>
<ul>
<li>五只我们更看好的股票超过 PureTech Health</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 PureTech Health 吗？</h2>
<p>在你考虑 PureTech Health 之前，你需要听听这个。</p>
<p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄建议客户在更广泛的市场注意到之前立即购买的股票……而 PureTech Health 并不在名单上。</p>
<p>虽然 PureTech Health 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

PRTC

PRTCY

<p>PureTech Health (伦敦证券交易所代码: PRTC) 的股价下跌了 9.2%，至 126 便士，交易量为 1,066,844 股，较平均交易量下降了 15%。该公司的市值为 3.0671 亿英镑，市盈率为 -2.74，债务与股本比率为 6.33。分析师目前对该股票的评级为 “买入”，但并不是顶级推荐。PureTech 专注于开发神经系统、胃肠道和免疫系统疾病的治疗方案</p>

<p>PureTech Health plc (LON:PRTC - Get Free Report)'s share price traded down 9.2% on Tuesday . The company traded as low as GBX 126 and last traded at GBX 126. 1,066,844 shares traded hands during mid-day trading, a decline of 15% from the average session volume of 1,249,921 shares. The stock had previously closed at GBX 138.80.</p>
<div class="lb-trans"><p>PureTech Health plc (LON:PRTC - 获取免费报告) 的股价在周二下跌了 9.2%。该公司的股价最低曾达到 126 便士，最后交易价为 126 便士。在午盘交易中，共成交了 1,066,844 股，较平均交易量 1,249,921 股下降了 15%。该股票此前收盘价为 138.80 便士。</p>
</div><p>Get <strong>PureTech Health</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>PureTech Health</strong> 的提醒：</p>
</div><h2>PureTech Health Stock Performance</h2>
<div class="lb-trans"><h2>PureTech Health 股票表现</h2>
</div><p>The company has a debt-to-equity ratio of 6.33, a current ratio of 6.59 and a quick ratio of 2.51. The stock has a market capitalization of £306.71 million, a PE ratio of -2.74 and a beta of 1.35. The stock has a 50 day moving average of GBX 121.85 and a two-hundred day moving average of GBX 125.88.</p>
<div class="lb-trans"><p>该公司的债务与股本比率为 6.33，流动比率为 6.59，速动比率为 2.51。该股票的市值为 3.0671 亿英镑，市盈率为-2.74，贝塔值为 1.35。该股票的 50 日移动平均线为 121.85 便士，200 日移动平均线为 125.88 便士。</p>
</div><h2>PureTech Health Company Profile</h2>
<div class="lb-trans"><h2>PureTech Health 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.</p>
<div class="lb-trans"><p>PureTech Health plc 是一家临床阶段的生物制药公司，专注于开发针对神经、胃肠和免疫系统功能障碍引起的疾病的药物。该公司正在开发微生物组免疫系统药物发现平台和针对免疫介导疾病的药物候选者；以及通过口服胶囊诱导减肥和增强血糖控制的产品。它还在开发用于筛查、诊断和治疗神经系统疾病（如注意力缺陷多动障碍、自闭症和抑郁症）的技术和产品；用于精神疾病的非侵入性神经刺激治疗；以及用于精神分裂症的联合治疗。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>特色故事</h2>
</div><ul>
<li>Five stocks we like better than PureTech Health</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 PureTech Health</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in PureTech Health Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 PureTech Health 吗？</h2>
</div><p>Before you consider PureTech Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 PureTech Health 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄建议客户在更广泛的市场注意到之前立即购买的股票……而 PureTech Health 并不在名单上。</p>
</div><p>While PureTech Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 PureTech Health 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

PureTech Health (LON:PRTC) 股价下跌 9.2% - 现在是卖出的时候吗？